What Krystexxa treats
Krystexxa (pegloticase) is a biologic medication used to treat chronic gout that is not controlled by standard oral medications. It is specifically indicated for patients with uncontrolled or treatment-resistant gout, particularly those with high uric acid levels and debilitating symptoms. Krystexxa works by rapidly lowering uric acid levels, helping to dissolve existing urate crystals and relieve gout symptoms.
Benefits of Krystexxa
Patients receiving Krystexxa may experience:
- Rapid and significant reductions in serum uric acid levels
- Resolution or shrinkage of tophi
- Decreased frequency and severity of gout flares over time
- Improved mobility and joint function in severe cases
For many patients with refractory gout, Krystexxa can lead to life-changing relief after years of painful symptoms.
Possible Side Effects of Krystexxa
Common side effects may include:
- Gout flares (especially during early treatment)
- Nausea
- Bruising or irritation at the infusion site
Serious side effects, though rare, include:
- Infusion reactions or allergic responses
- Risk of anaphylaxis (patients are typically pre-treated with antihistamines and corticosteroids)
- Hemolysis in patients with G6PD deficiency (testing is required before starting therapy)
Patients are monitored closely during infusions to manage any adverse effects.
How infusion works at Prime
Krystexxa is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Krystexxa, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Krystexxa Work?
Krystexxa works by converting uric acid into a harmless substance called allantoin, which is easily excreted by the body. This is accomplished through its active enzyme, pegloticase, a recombinant uricase that breaks down uric acid. Unlike standard gout medications that slow uric acid production or increase its excretion, Krystexxa removes uric acid directly from the bloodstream. It is administered via intravenous infusion every two weeks.
Who is Krystexxa For?
Krystexxa is intended for adults with chronic gout who have not achieved symptom control with other urate-lowering therapies such as allopurinol or febuxostat. It is particularly effective for patients with:
- Tophi (deposits of urate crystals in joints or soft tissues)
- Severe, frequent gout flares
- Contraindications or intolerance to oral gout medications
Krystexxa is used when conventional therapies are ineffective or inappropriate.